← Back to Screener
Pluri Inc. Common Stock (PLUR)
Price$3.62
Favorite Metrics
Price vs S&P 500 (26W)-27.94%
Price vs S&P 500 (4W)6.91%
Market Capitalization$36.38M
All Metrics
Book Value / Share (Quarterly)$0.02
P/TBV (Annual)1.89x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)78.73%
Cash Flow / Share (Quarterly)$-2.21
Price vs S&P 500 (YTD)17.12%
Gross Margin (TTM)40.63%
Net Profit Margin (TTM)-1952.05%
EPS (TTM)$-3.27
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-3.27
Revenue Growth (5Y)125.33%
EPS (Annual)$-3.56
ROI (Annual)-86.59%
Gross Margin (Annual)48.95%
Net Profit Margin (5Y Avg)-32518.38%
Cash / Share (Quarterly)$1.25
Revenue Growth QoQ (YoY)7.03%
ROA (Last FY)-58.38%
Revenue Growth TTM (YoY)97.49%
EBITD / Share (TTM)$-2.93
ROE (5Y Avg)-4450.31%
Operating Margin (TTM)-1857.88%
Cash Flow / Share (Annual)$-2.51
P/B Ratio379.00x
P/B Ratio (Quarterly)323.05x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)44.64x
Net Interest Coverage (TTM)-13.22x
ROA (TTM)-74.49%
EPS Incl Extra (Annual)$-3.56
Current Ratio (Annual)0.68x
Quick Ratio (Quarterly)0.43x
3-Month Avg Trading Volume0.02M
52-Week Price Return-7.06%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.21
P/S Ratio (Annual)27.23x
Asset Turnover (Annual)0.03x
52-Week High$7.13
Operating Margin (5Y Avg)-32776.30%
EPS Excl Extra (Annual)$-3.56
CapEx CAGR (5Y)43.06%
Tangible BV CAGR (5Y)-14.07%
26-Week Price Return-19.20%
Quick Ratio (Annual)0.68x
13-Week Price Return11.84%
Total Debt / Equity (Annual)250.28x
Current Ratio (Quarterly)0.43x
Enterprise Value$59.776
Revenue / Share Growth (5Y)83.62%
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)-33.61%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1740.64%
Cash / Share (Annual)$2.61
3-Month Return Std Dev59.46%
Gross Margin (5Y Avg)88.18%
Net Income / Employee (TTM)$-0
ROE (Last FY)-21758.33%
Net Interest Coverage (Annual)-5.95x
EPS Basic Excl Extra (Annual)$-3.56
Receivables Turnover (TTM)0.46x
Total Debt / Equity (Quarterly)250.28x
EPS Incl Extra (TTM)$-3.27
Receivables Turnover (Annual)3.00x
ROI (TTM)-55.04%
P/S Ratio (TTM)27.17x
Pretax Margin (5Y Avg)-32556.41%
Revenue / Share (Annual)$0.21
Tangible BV / Share (Annual)$0.32
Price vs S&P 500 (52W)-42.16%
Year-to-Date Return21.07%
5-Day Price Return8.36%
EPS Normalized (Annual)$-3.56
ROA (5Y Avg)-56.44%
Net Profit Margin (Annual)-1690.34%
Month-to-Date Return6.63%
Cash Flow / Share (TTM)$-0.70
EBITD / Share (Annual)$-3.36
Operating Margin (Annual)-1659.88%
LT Debt / Equity (Annual)250.28x
ROI (5Y Avg)-71.69%
LT Debt / Equity (Quarterly)250.28x
EPS Basic Excl Extra (TTM)$-3.27
P/TBV (Quarterly)2.84x
P/B Ratio (Annual)323.05x
Pretax Margin (TTM)-2026.06%
Book Value / Share (Annual)$0.02
Price vs S&P 500 (13W)8.97%
Beta0.80x
Revenue / Share (TTM)$0.14
ROE (TTM)-349.25%
52-Week Low$2.82
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PLURPluri Inc. Common Stock | 27.17x | 97.49% | 40.63% | — | $3.62 |
AMGNAmgen Inc | 5.21x | 9.95% | 73.30% | 2.93% | $355.30 |
GILDGilead Sciences Inc | 5.80x | 2.40% | 78.83% | 133.64% | $137.64 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $849.04 |
BNTXBioNTech SE American Depositary Share | 8.99x | -11.81% | 84.21% | — | $102.92 |
BIIBBiogen Inc. Common Stock | 2.63x | 2.22% | 75.69% | -18.77% | $177.35 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $53.72 |
NBIXNeurocrine Biosciences Inc | 4.68x | 21.45% | 98.18% | 2.31% | $133.25 |
EXELExelixis Inc | 5.02x | 6.85% | 96.39% | 31.10% | $44.89 |
TECHBio-Techne Corp. | 7.62x | 1.64% | 66.60% | -20.58% | $59.23 |
HALOHalozyme Therapeutics, Inc. | 5.88x | 37.55% | 83.62% | 22.89% | $69.29 |
About
Pluri Inc develops cell-based therapeutics using its proprietary 3D cell expansion platform, targeting regenerative medicine, immunotherapy, and hematologic diseases. The company generates revenue through CDMO services while advancing placenta-derived cell therapy candidates for inflammatory and musculoskeletal conditions. Pluri is also exploring applications in cultivated alternative proteins.